Karyopharm Therapeutics (KPTI)
(Delayed Data from NSDQ)
$0.88 USD
-0.01 (-0.61%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $0.87 -0.01 (-0.78%) 5:04 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.88 USD
-0.01 (-0.61%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $0.87 -0.01 (-0.78%) 5:04 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Zacks News
Do Options Traders Know Something About Karyopharm (KPTI) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Karyopharm (KPTI) stock based on the movements in the options market lately.
What's in Store for AstraZeneca (AZN) This Earnings Season?
by Zacks Equity Research
AstraZeneca's (AZN) fourth-quarter results are expected to reflect the impact of new drug sales.
What's in Store for Acorda (ACOR) This Earnings Season?
by Zacks Equity Research
During Acorda's (ACOR) Q4 earnings call, investor focus will be on the sales uptake of its newly-launched Parkinson's disease drug Inbrija.
What's in Store for Ironwood (IRWD) This Earnings Season?
by Zacks Equity Research
Ironwood Pharmaceuticals' (IRWD) Linzess is likely to have driven total revenues in the fourth quarter.
Options Traders Expect Huge Moves in Karyopharm (KPTI) Stock
by Zacks Equity Research
Investors need to pay close attention to Karyopharm (KPTI) stock based on the movements in the options market lately.
BioLineRx's Pancreatic Cancer Drug Gets Orphan Drug Tag in EU
by Zacks Equity Research
The European Commission bestows an orphan drug status on BioLineRx's (BLRX) lead candidate Motixafortide, currently being evaluated with Merck's Keytruda to treat pancreatic cancer. Stock up.
Aclaris' MK2 Inhibitor Shows Encouraging Data in Phase I
by Zacks Equity Research
Aclaris (ACRS) announces favorable preliminary data from the phase I study on its investigational candidate ATI-450, presently being developed for treating immuno-inflammatory diseases. Stock rises.
Top Ranked Momentum Stocks to Buy for January 13th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, January 13th
Zacks.com featured highlights include: Cassava Sciences, Rubicon Project, Talos Energy, Teekay Tankers and Karyopharm Therapeutics
by Zacks Equity Research
Zacks.com featured highlights include: Cassava Sciences, Rubicon Project, Talos Energy, Teekay Tankers and Karyopharm Therapeutics
5 Stocks With Recent Price Strength for Spectacular Returns
by Nalak Das
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Are You Looking for a Top Momentum Pick? Why Karyopharm Therapeutics (KPTI) is a Great Choice
by Zacks Equity Research
Does Karyopharm Therapeutics (KPTI) have what it takes to be a top stock pick for momentum investors? Let's find out.
Karyopharm (KPTI) Catches Eye: Stock Jumps 6.4%
by Zacks Equity Research
Karyopharm (KPTI) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 20.24% and 718.23%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Karyopharm Signs $150M Royalty Agreement to Support Xpovio
by Zacks Equity Research
Karyopharm (KPTI) signs royalty agreement with HealthCare Royalty Partners for up to $150 million to fund Xpovio's commercialization and development.
Bristol-Myers' (BMY) Opdivo Falls Flat in Brain Tumor Study
by Zacks Equity Research
Bristol-Myers (BMY) announces dismal results from a late-stage study on its immuno-oncology drug Opdivo for critical brain tumor.
Earnings Preview: Karyopharm Therapeutics (KPTI) Q2 Earnings Expected to Decline
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Karyopharm Therapeutics Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Karyopharm Therapeutics.
Karyopharm Gets Accelerated FDA Approval for Myeloma Drug
by Zacks Equity Research
Karyopharm (KPTI) gets accelerated FDA approval for oral Xpovio in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma.
Implied Volatility Surging for Karyopharm Therapeutics (KPTI) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Karyopharm Therapeutics (KPTI) stock based on the movements in the options market lately.
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -29.76% and -79.39%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Karyopharm Therapeutics (KPTI) Q1 Earnings Expected to Decline
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Karyopharm Stock Up Even as FDA Delays Selinexor NDA Verdict
by Zacks Equity Research
Karyopharm's (KPTI) stock rises despite the FDA's decision to delay the verdict on the NDA filing of selinexor, which is developed for treating patients with relapsed-refractory multiple myeloma.
Karyopharm Files MAA for Myeloma Candidate Selinexor in EU
by Zacks Equity Research
Karyopharm (KPTI) tenders a marketing application to European regulatory authority with the purpose of seeking an approval for selinexor to address patients with penta-refractory multiple myeloma.
Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 10.23% and -80.25%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 21.05% and 233.07%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?